Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world GM-CSF plus PD-1/PD-L1 inhibitors in advanced solid tumors
ChiCTR2200058006Phase 4Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sargramostim in Nonhematologic neoplasms, sponsored by First Hospital of China Medical University. Primary endpoints: Objective remission rate and Progression-free survival. Started Apr 2022; status: recruiting.
02
Drugs
sargramostim
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2200058006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058006.